|
|
Post by harryx1 on May 27, 2015 9:24:51 GMT -5
|
|
|
|
Post by compound26 on May 27, 2015 10:46:31 GMT -5
LOL about the last paragraph.  "In addition to reporting the current status of the development of inhaled insulin, our report illustrates a simple but important truth: making an innovative product take root can only be regarded as an initial success, to make it flourish and bear fruit, intensive care is needed. MannKind is doing so." |
|
|
|
Post by robsacher on May 27, 2015 10:50:07 GMT -5
I also love this awkward translation:
After MannKind and Sanofi increased propaganda, May 19, according to Los Angeles Times "MannKind stock jumps onpositive report about inhaled insulin" one paper reported, and now physician awareness of Afrezza improved, physicians in clinical practice has been increasingly The more prescription Afrezza, especially for type I diabetes.
If inhaled insulin can be universally applied, Afrezza may have the best chance.
This paper reports the dynamic addition of inhaled insulin product, but illustrates a simple but important truth: innovative projects take root only be regarded as initial success, to make it flourish, bear fruit, need intensive care, MannKind company is so I do.
|
|
|
|
Post by BD on May 27, 2015 13:51:57 GMT -5
Reminds me of a punny joke that made the rounds several years back:
Did you hear? Picabo Street (the skier) has been working at my local hospital, in the intensive care unit.
She answers the phone, "Picabo, ICU!"
|
|
